Transatlantic expansion
RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations have demonstrated the increased safety and faster workflow that RebrAIn’s AI targeting solution enables for MR-guided Focused Ultrasound (MRgFUS) thalamotomy in patients with severe essential tremor, as highlighted in abstracts and presentations at recent neurosurgery conferences.
Strategic partnerships
We are actively engaging in multiple strategic discussions with neuro OEMs to expand our presence across the full spectrum of functional neurosurgery treatments. RebrAIn positions itself as a clinical AI advisor for multiple therapeutic solutions for brain disorders, establishing partnerships that will enable us to grow and scale more rapidly.
Adoption and deployment
Since the company’s inception, we have performed 955 targeting procedures, a 4x increase compared to 2024. Our 16 contracted sites are evenly split between the USA (8) and Europe (8), reflecting steady, balanced international growth.
Team and leadership
RebrAIn now employs 22 professionals, including the recent addition of an experienced Chief of Commercial Growth for the USA, bringing 25 years of MedTech and neurosurgery sales and marketing experience.
Innovation and technology
A new version of our software is about to be filed with the FDA, offering near real-time targeting through our automatic labeling and subthalamic region segmentation. Our infrastructure continues to evolve with SOC2 readiness, ensuring the highest level of cybersecurity and data protection for hospitals. This second iteration for MDR/FDA submission is planned for Q1 2026.
Clinical research
- The OPTIVIM Essential Tremor trial, quantifying the precision of RebrAIn’s targeting for deep brain stimulation surgery, was published in Neurosurgery (Jan 2026) [LINK].
- The PARKEO2 randomized controlled trial involving 128 Parkinson’s patients has completed patient inclusion and 12-month follow-up and is now entering the data analysis phase.
- OPTIRS, our RCT on Gamma Knife in Marseille, is about to treat its first patient.
- Our new prospective MRgFUS clinical trial protocol in the USA is being finalized.
Financing
To accelerate our commercialization efforts, particularly in the U.S., and to further develop our solutions, we are preparing a Series A round. We anticipate closing the round around spring 2026.
